News

Generic drugs will soon break out, pharmaceutical intermediaries usher in a good opportunity for dev

  • Author:Jane
  • Source:前瞻产业研究院
  • Release on :2017-07-27
Pharmaceutical intermediates have been concerned about and favored by all walks of life. Our government also attaches great importance to the development of pharmaceutical intermediates, introduced a series of incentives and initiatives. Driven by the government, China's pharmaceutical intermediates industry is developing rapidly. At present, has basically met the pharmaceutical production of chemical raw materials and intermediates.


According to the prospective industry research institute released the "China pharmaceutical intermediates industry market research and investment analysis report" is expected, with the patent drug expires, the next five to ten years, generic drugs will usher in the price advantage of explosive growth, production and sales Is expected to soar. The outbreak of generic drugs, medicine intermediates will bring a broader market space and good development opportunities, the future prospects can be expected.

Pharmaceutical intermediates are used in the pharmaceutical synthesis process in a number of chemical raw materials or chemical products, but also an important part of fine chemicals, has gradually become the core of the development of chemical industry. In recent years, China has made great progress in fine chemicals, fine rate of continuous improvement for the development of pharmaceutical intermediates to create a good atmosphere.

As a result of high investment efficiency, high profit margins, high added value, pharmaceutical intermediates have been concerned about and favored by all walks of life. Our government also attaches great importance to the development of pharmaceutical intermediates, introduced a series of incentives and initiatives.

Driven by the government, China's pharmaceutical intermediates industry is developing rapidly. At present, has basically meet the pharmaceutical production required for chemical raw materials and intermediates, and presents the following six characteristics.

First, the pharmaceutical intermediaries are mostly private enterprises, the investment scale is generally small, the basic investment in the millions to 20 million, but the operation is more flexible, able to quickly respond to market changes;

Second, the distribution of pharmaceutical intermediates are more concentrated, mainly in Jiangsu and Zhejiang, especially Zhejiang Taizhou, Jiangsu Jintan two, gathered a large number of pharmaceutical intermediates business;

Third, the pharmaceutical intermediates enterprises are facing increasing pressure on environmental protection, construction of environmental protection facilities is imperative;

Fourth, the product update iterative fast, new varieties of endless, forcing pharmaceutical intermediates to follow up or improve the process;

Fifth, the pharmaceutical intermediates industry competition is fierce and disorder, more and more small and medium-sized chemical enterprises are joining them, is not conducive to the pharmaceutical intermediates industry cluster development;

Sixth, pharmaceutical intermediates generally lack of innovation, there is a low level of duplication, in the world with independent intellectual property rights of intermediate drugs only a handful.

From the above development characteristics, China's pharmaceutical intermediates and the international advanced level is also very different. In the future to promote the development of pharmaceutical intermediates industry, we should pay attention to scientific research investment, to interdisciplinary, multi-faceted, high starting point for the establishment of engineering center for the birth of new products platform, at the same time to carry out forecasting and evaluation work to achieve rapid and healthy development of pharmaceutical intermediates The

In general, with the Chinese pharmaceutical companies generous generics, pharmaceutical intermediates are expected to benefit, but before that, the need to address excess capacity, vicious competition and other issues.